The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, announced its participation in the upcoming B. Riley's 25th Annual Institutional Investor Conference. The event will take place on May 21st, 2025, in Marina Del Rey, CA. The company will be represented by CEO Dr. Daniel Virnich and CFO Rob Carter.
L'Istituto di Oncologia (NASDAQ: TOI), un importante gruppo oncologico basato sul valore negli Stati Uniti, ha annunciato la sua partecipazione al prossimo 25° Congresso Annuale per Investitori Istituzionali di B. Riley. L'evento si terrà il 21 maggio 2025 a Marina Del Rey, CA. La società sarà rappresentata dal CEO Dr. Daniel Virnich e dal CFO Rob Carter.
El Instituto de Oncología (NASDAQ: TOI), un destacado grupo oncológico basado en el valor en Estados Unidos, anunció su participación en la próxima 25ª Conferencia Anual para Inversionistas Institucionales de B. Riley. El evento tendrá lugar el 21 de mayo de 2025 en Marina Del Rey, CA. La compañía estará representada por el CEO Dr. Daniel Virnich y el CFO Rob Carter.
온콜로지 연구소 (NASDAQ: TOI)는 미국을 대표하는 가치 중심의 종양학 그룹으로서, 다가오는 B. Riley 제25회 연례 기관 투자자 컨퍼런스에 참여할 것임을 발표했습니다. 행사는 2025년 5월 21일, 캘리포니아 마리나 델 레이에서 개최됩니다. 회사는 CEO Dr. Daniel Virnich와 CFO Rob Carter가 대표로 참석할 예정입니다.
L'Institut d'Oncologie (NASDAQ : TOI), un groupe oncologique de premier plan axé sur la valeur aux États-Unis, a annoncé sa participation à la prochaine 25e Conférence Annuelle des Investisseurs Institutionnels de B. Riley. L'événement se tiendra le 21 mai 2025 à Marina Del Rey, en Californie. La société sera représentée par le PDG Dr Daniel Virnich et le directeur financier Rob Carter.
Das Oncology Institute (NASDAQ: TOI), eine führende wertorientierte Onkologiegruppe in den USA, gab seine Teilnahme an der bevorstehenden 25. jährlichen institutionellen Investorenkonferenz von B. Riley bekannt. Die Veranstaltung findet am 21. Mai 2025 in Marina Del Rey, Kalifornien, statt. Das Unternehmen wird durch CEO Dr. Daniel Virnich und CFO Rob Carter vertreten sein.
- None.
- None.
CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025.
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.
For more information, visit www.theoncologyinstitute.com
Contacts
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
When is The Oncology Institute (TOI) presenting at the B. Riley Conference?
Who will represent TOI at the B. Riley Institutional Investor Conference?
What is The Oncology Institute's (TOI) position in the oncology market?
What is TOI's stock exchange listing?
